Darolutamide

Drug Profile

Darolutamide

Alternative Names: BAY 1841788; ODM 201

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Orion
  • Developer Bayer HealthCare; Institute Gustave-Roussy; Orion; Swiss Group for Clinical Cancer Research
  • Class Amides; Antiandrogens; Antineoplastics; Pyrazoles; Small molecules
  • Mechanism of Action Androgen receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Prostate cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Prostate-cancer(Metastatic disease) in Latvia (PO, Capsule)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Prostate-cancer(Metastatic disease) in Latvia (PO, Tablet)
  • 10 Oct 2017 Phase-II clinical trials in Prostate cancer (Second-line therapy or greater, Metastatic disease) in France (PO) (EudraCT2017-001606-14)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top